[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-inflammatory-demyelinating-polyneuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-inflammatory-demyelinating-polyneuropathy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,41,63,88,114,126,148,169,197,209,254,281,306,333,364,389,414],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053627","phase-3-a-study-to-test-the-efficacy-and-safety-of-riliprubart-against-the-usual-treatment-of-intravenous-immunoglobulin-ivig-in-people-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100053627",false,"NCT06290141","A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy","VITALIZE","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n* Participant must have CIDP or possible CIDP criteria, based on European Academy of Neurology (EAN)\u002FPeripheral Nerve Society (PNS) Task Force CIDP guidelines, second revision (2021).\n* Participant must have either typical CIDP, or one of the following 2 CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis Sumner Syndrome). Diagnosis must be confirmed by the study adjudication committee.\n* Participants must have responded to IVIg in the past 5 years.\n* Participant must be on a stable maintenance dosage of IVIg.\n* Participant must have residual disability, defined as an INCAT score of 2 to 9 at Screening that is confirmed at baseline (a score of 2 should be exclusively from leg disability component of INCAT).\n* Participant must be receiving treatment with IVIg within a standard maintenance dosing regimen, defined as per EAN\u002FPNS 2021 CIDP guidelines.\n* Participants receiving IVIg infusions at home are eligible, as long as IVIg infusions are switched to a hospital or infusion center setting at least 1 cycle prior to baseline.\n* Participant must have active disease, defined by a CIDP disease activity score (CDAS) of ≥2 points at Screening.\n* Participant must have documented vaccinations against encapsulated bacterial pathogens given within 5 years prior to Day 1 or initiated a minimum of 14 days prior to first dose of study intervention.\n* Contraception for sexually active male or female participants; not pregnant or breastfeeding; no sperm donating for male participant\n* Participant must have a body weight at Screening of 35 kg to 154 kg (77 to 340 lbs) inclusive.\n* Evidence of at least one clinically meaningful deterioration within 2 years, or at least 2 clinically meaningful deteriorations within 5 years prior to screening which occurred during period of interrupted dosing, reduced dosage, or extended intervals between doses of immunoglobin therapy, as verified by clinical examination or medical records.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Polyneuropathy of other causes, including but not limited to acute demyelinating polyneuropathies (eg, Guillain-Barré syndrome), hereditary demyelinating neuropathies, neuropathies secondary to infection or systemic disease, diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy, polyneuropathy related to IgM monoclonal gammopathy, POEMS syndrome, lumbosacral radiculoplexus neuropathy.\n* Sensory CIDP, distal CIDP and focal CIDP variants.\n* Any other neurological or systemic disease that can cause symptoms and signs interfering with treatment or outcome assessments.\n* Poorly controlled diabetes\n* Serious infections requiring hospitalization within 30 days prior to Screening, any active infection requiring antimicrobial treatment during Screening, or presence of a condition that may predispose the participant to increased risk of infection (eg, medical history such as known immunodeficiency or history of recurrent infections).\n* Clinical diagnosis of Systemic Lupus Erythematosus (SLE) or family history of SLE. For a participant with an antinuclear antibody (ANA) titer ≥1:160 and a positive anti double-stranded DNA (anti-dsDNA) at Screening, SLE diagnosis must be ruled out prior to enrollment.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study. Specifically, history of any hypersensitivity reaction to riliprubart or its components or of a severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody.\n* Any contraindication related to the administration of immunoglobulins (eg hypersensitivity, chronic kidney disease, thromboembolic diseases or recent thromboembolic event, known history of IgA deficiency at the time of Screening).\n* Any other clinically meaningful medical history or ongoing medical condition (as determined by the Investigator at Screening) that might impact the benefit-risk assessment, jeopardize the safety of the participant, or compromise the quality of the data collected in this study; or history or presence of other significant concomitant illness that would adversely affect participation in this study, per the Investigator's judgment.\n* Documented history of attempted suicide over the 6 months prior to the Screening visit, presence of suicidal ideation of category 4 or 5 on the C-SSRS during Screening, OR if in the Investigator's judgment, the participant is at risk for a suicide attempt.\n* Evidence of CIDP worsening within the 6 weeks following a prior vaccination that, in the opinion of the Investigator, constituted a relapse.\n* Recent or planned major surgery that could confound the results of the trial or put the participant at undue risk.\n* Recent treatment with plasma exchange\n* Treatment within 3 months prior to dosing with immunosuppressive\u002F immunomodulator medication, or corticosteroids (with exception of maintenance dose, which is allowed), or prior treatment (at any time) with highly immunosuppressive\u002F chemotherapeutic medications with sustained effects (eg, mitoxantrone, alemtuzumab, or cladribine).\n* Prior treatment with riliprubart.\n* Recent use of any specific complement system inhibitor (eg, eculizumab).\n* Prior treatment (any time) with total lymphoid irradiation or bone marrow transplantation.\n* Prior treatment with B-cell depleting agents such as rituximab within 6 months.\n* Any vaccination received within 28 days prior to dosing (with few exceptions to be confirmed at screening).\n* Participation in another clinical trial with an investigational drug or receipt of an investigational product within 12 weeks or 5 times the half-life of the product (whichever is longer) prior to Screening.\n* Any Screening laboratory values outside normal limits or abnormal ECG considered in the Investigator's judgment to be clinically significant in the context of this trial.\n* Positive result of any of the following tests:\n\n  * hepatitis B surface antigen (HbsAg).\n  * anti-hepatitis B core antibodies (anti-HBc Ab) (unless anti-hepatitis B surface antibodies \\[anti-HBs Ab\\] are also positive, indicating natural immunity).\n  * anti-hepatitis C virus (anti-HCV) antibodies. Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis RNA test is obtained.\n  * anti-human immunodeficiency virus 1 and 2 (anti-HIV1 and anti-HIV2) antibodies.\n* Pregnancy, defined as a positive result of a highly sensitive urine or serum pregnancy test, or lactation.\n* Accommodation in an institution because of regulatory or legal order; imprisoned or legally institutionalized.\n* Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.\n* Participants are employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.\n* Any country-related specific regulation that would prevent the participant from entering the study as defined by the protocol.\n* Recent treatment with efgartigimod.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.",[27],"Chronic Inflammatory Demyelinating Polyneuropathy","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2024-08-21",{"date":36,"type":21},"2029-01-12",{"name":38,"class":39},"Sanofi","INDUSTRY",129,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":62},"100053951","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-dnth103-in-adults-with-chronic-inflammatory-demyelinating-polyneuropathy-captivate-100053951","NCT06858579","A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","CAPTIVATE","Inclusion Criteria:\n\n1. Must have given written informed consent before any study-related activities are carried out.\n2. Weight range between 40 kilograms (kg) and 120 kg.\n3. Confirmed diagnosis of CIDP or possible CIDP. Participants must have either typical CIDP or one of the following variants: motor or multifocal CIDP. Diagnosis must be confirmed by the Independent CIDP Review Panel.\n4. CIDP Disease Activity Status (CDAS) score ≥ 3 at screening.\n5. Must be neurologically stable.\n6. Must have an INCAT score between 2 and 9 inclusive.\n7. Must fulfill one of the following treatment conditions for CIDP:\n\n   1. Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin \\[IVIg\\] or subcutaneous immunoglobulin \\[SCIg\\]) alone or Ig (IVIg or SCIg) plus oral corticosteroids, or previously treated with and responded to, but are no longer being treated with (eg, lost access to), a maintenance regimen of Ig (IVIg or SCIg) alone or Ig (IVIg or SCIg) plus oral corticosteroids.\n   2. Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil.\n   3. Refractory participants who have had treatment failure (worsening) or an inadequate response to Ig and\u002For oral corticosteroids (defined as no clinically meaningful improvement after a period of a minimum of 12 weeks, which may include both active treatment and observation to assess response), or who at any time were unable to tolerate these treatments, experienced adverse effects, or have documented contraindications.\n   4. Treatment naïve with no history of prior treatment for CIDP.\n8. Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability.\n9. Female participants must be of nonchildbearing potential or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of contraception.\n10. Male participants must agree not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception or be surgically sterile for at least 90 days prior to Screening.\n\nExclusion Criteria:\n\n1. Clinical signs or symptoms suggestive of polyneuropathy of causes other than CIDP.\n2. Known evidence of central demyelination or known history of myelopathy.\n3. History or presence of significant medical\u002Fsurgical condition including any acute illness or major surgery considered to be clinically significant or that could have a potential impact on safety\u002Fefficacy or study procedures.\n4. Any other condition, including mental illness or prior therapy that would make the participant unsuitable for this study.\n5. Known complement deficiency or history of positive titer for anti-C1 antibodies.\n6. Diagnosis of systemic lupus erythematosus (SLE) or family history of SLE (defined as a parent, sibling, or child).\n7. Participants with an autoimmune disease affecting joints, muscle or nervous system.\n8. Any coexisting or overlapping condition, which may interfere with outcome assessments, such as severe diabetic neuropathy, fibromyalgia, inflammatory arthritis or osteoarthritis affecting the hands and feet.\n9. Prior history of N. meningitidis infection.\n10. History of active malignancy within 5 years prior to screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone.\n11. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.","75 Years",{"count":51,"type":21},256,[24],"The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).",[27],{"date":31,"type":32},{"date":57,"type":32},"2025-02-10",{"date":59,"type":21},"2030-12-31",{"name":61,"class":39},"Dianthus Therapeutics",180,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100616326","phase-1-a-study-evaluating-the-safety-and-efficacy-of-kite-363-in-relapsedrefractory-autoimmune-neurologic-diseases-100616326","NCT07304154","A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed\u002FRefractory Autoimmune Neurologic Diseases","A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19\u002FCD20 CAR T-cell Therapy in Participants With Relapsed\u002FRefractory Autoimmune Neurologic Diseases","Key Inclusion Criteria:\n\n* Reproductive status-related eligibility and contraception requirements:\n\n  * Participants must agree to use protocol-specified method(s) of contraception where applicable\n\nInclusion Criteria for multiple sclerosis (MS):\n\nMS (Relapsing and progressive forms):\n\n* Diagnosed with MS according to the 2017 revision of the McDonald diagnostic criteria\n\nRelapsing forms of MS (relapsing-remitting multiple sclerosis (RRMS), active secondary-progressive multiple sclerosis (aSPMS)):\n\n* Inadequate response to previous therapies is defined as evidence of breakthrough disease activity within 12 months prior to screening while on high efficacy disease-modifying therapy (DMT) OR Inadequate response to previous therapies defined as intolerance to ≥ 2 DMTs due to side effects prohibiting the chronic use of the DMT.\n* Expanded Disability Status Scale (EDSS) 0 to 5.5\n\nProgressive forms of MS (primary-progressive multiple sclerosis (PPMS) and non-active secondary-progressive multiple sclerosis (naSPMS)):\n\n* Inadequate response to previous therapies is defined as evidence of disease progression within 12 months prior to screening despite standard of care therapy for naSPMS or despite ocrelizumab, where available, for PPMS\n* Absence of clinical relapses for at least 24 months\n* No evidence of Gadolinium enhancing (GadE+) on magnetic resonance imaging (MRI) brain at screening or baseline\n* EDSS of 3 to 6.5 who are ambulatory\n\nInclusion Criteria for myasthenia gravis (MG):\n\n* Documentation of autoantibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4)\n* Diagnosis of MG with generalized weakness meeting criteria as defined by the Myasthenia Gravis Foundation of American (MGFA) classification of II- IV at screening\n* Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 6 (\\> 50% of the total score due to non-ocular symptoms)\n* Quantitative Myasthenia Gravis (QMG) score ≥ 10\n* Inadequate response to previous therapies while taking at least 2 classes of immunosuppressants (ie, steroids, azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-neonatal fragment crystallizable (Fc) receptor (FcRN) class, and anti-complement class))\n* Thymectomy allowed if completed ≥ 12 months prior to screening\n\nInclusion Criteria for chronic inflammatory demyelinating polyneuropathy (CIDP):\n\n* Probable or definite CIDP as defined by the 2010 European Federation of Neurological Societies\u002FPeripheral Nerve Society (EFNS\u002FPNS) criteria, relapsing or progressive forms\n* CIDP Disease Activity Status (CDAS) score ≥ 3 at screening\n* Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3\n* Inadequate response to previous therapies despite standard of care therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN) OR Unable to tolerate standard of care due to side effects with ongoing disease activity\n* Except for nodal\u002Fparanodal CIDP, historical documentation of objective improvement in the past 24 months while on IVIg, SCIg, PLEX, or anti-FcRN OR Historical documentation of objective disease worsening in the past 24 months when IVIg, SCIg, PLEX, or anti-FcRN has been reduced or interrupted\n\nKey Exclusion Criteria:\n\n* History or presence of central nervous system (CNS) or peripheral nervous system disorders before enrollment that may impact cognition, strength, or cause weakness\n* History of autologous or allogeneic stem cell transplant and\u002For organ transplant\n\nExclusion Criteria for MS:\n\n* Cohort 1 or 2; inability to complete 9-hole Peg Test (9-HPT) in \\\u003C 240 seconds and Timed 25 foot Walk (T25FW) \\\u003C 150 seconds\n* History of hypersensitivity to parenteral administration of gadolinium-based contrast agents\n* Any renal condition that would preclude the administration of gadolinium (for the relapsing forms of MS and progressive forms of MS)\n* Any contraindication to lumbar puncture (LP) (for the relapsing forms of MS and progressive forms of MS)\n\nExclusion Criteria for MG:\n\n* Current myasthenic crisis not effectively controlled within 2 weeks before enrollment\n* Thymectomy performed within 12 months of baseline\n\nExclusion Criteria for CIDP:\n\n* Pure sensory CIDP and focal CIDP\n* Polyneuropathy of other causes\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":71,"type":21},52,[73],"PHASE1","This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed\u002Frefractory autoimmune neurologic diseases.\n\nThe primary objectives of this study are:\n\n* To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases\n* To determine the recommended dose for Phase 1b.\n* To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.",[27,76,77],"Myasthenia Gravis","Multiple Sclerosis","2026-06-30",{"date":80,"type":32},"2026-07-01",{"date":82,"type":32},"2026-04-10",{"date":84,"type":21},"2029-06",{"name":86,"class":39},"Kite, A Gilead Company",6,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100573905","phase-3-a-study-investigating-intravenous-human-normal-immune-globulin-igiv-10-kig10-qivigy-in-subjects-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100573905","NCT06752356","A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","A Double-blind, Randomized, Multi-Center Study Investigating Efficacy and Safety of Two Different Dosages of Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Inclusion Criteria:\n\n1. Male or female, aged ≥18 years.\n2. Written informed consent and authorization to access personal health information obtained independently from participants indicating that they understand the purpose of, and procedures required for, the study and are willing to participate.\n3. Documented diagnosis of CIDP consistent with the 2021 European Academy of Neurology\u002FPeripheral Nerve Society (EAN\u002FPNS) criteria.\n4. Current or documented history of significant disability, as defined by an overall INCAT disability score between 2 and 9. A score of 2 must be exclusively from the lower extremities.\n5. Participants are currently dependent on treatment with immunoglobulins, corticosteroids, or standard of care treatments for CIDP.\n6. Weakness of at least two limbs.\n7. Participants should be clinically stable 12 weeks prior to screening date as defined by:\n\n   * without a worsening in INCAT score of ≥1 point, AND\u002FOR without significant changes in clinical symptoms AND\n   * without significant dose changes or requiring additional treatments.\n\nExclusion Criteria:\n\n1. Patients' incapable of giving informed consent.\n2. Pure sensory and other CIDP variants.\n3. Females who are pregnant, breastfeeding, unwilling to practice effective birth control methods as defined in Appendix C throughout the study, or planning a pregnancy during the study.\n4. IG-experienced participants requiring an IGIV dosage of more than 1.4 g\u002Fkg\u002Fmonth OR SCIG pre-treated participants requiring a SCIG dosage of more than 1.6 g\u002Fkg\u002Fmonth.\n5. Participants who have previously failed to respond to IGIV or SCIG.\n6. On screening date, a body mass index (BMI) \\> 35 kg\u002Fm2 or an IGIV dose that puts the patient at risk of fluid overload.\n7. CIDP and any neuropathy of other causes not consistent with the 2021 EAN\u002FPNS criteria including:\n\n   1. Hereditary demyelinating neuropathies, such as a hereditary sensory and motor neuropathy (HSMN) (Charcot-Marie-Tooth \\[CMT\\] disease), and hereditary sensory and autonomic neuropathies (HSANs).\n   2. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexopathy or neuropathy, lymphoma, and amyloidosis.\n   3. Multifocal motor neuropathy (MMN).\n   4. Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy. Peripheral neuropathy induced by vitamin B12 deficiency.\n8. Immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with increased titers of antibodies to myelin-associated glycoprotein.\n9. Central demyelinating disorders (e.g, multiple sclerosis) or severe myopathy.\n10. Any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of CIDP or outcome measures (e.g., severe arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy) \\[participants with clinically diagnosed diabetes mellitus, who have adequate glycemic control with Hemoglobin A1C (HbA1C) of \\\u003C7.5% at screening, and who agree to maintain adequate glycemic control during the study are allowed\\].\n11. Congestive heart failure (New York Heart Association (NYHA) Class III\u002FIV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension \\[i.e., diastolic blood pressure \\>100 mmHg and\u002For systolic blood pressure \\>160 mmHg\\]. If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used.\n12. History of deep vein thrombosis or thromboembolic events (e.g, cerebrovascular accident, pulmonary embolism) in the past 12 months.\n13. Condition(s) which could alter protein catabolism and\u002For IgG utilization (e.g, protein-losing enteropathies, nephrotic syndrome).\n14. Known history of chronic kidney disease, or glomerular filtration rate (GFR) of \\\u003C60 milliliter per minute per 1.73 square meter (mL\u002Fmin\u002F1.73m2) estimated based on an established chronic kidney disease epidemiology collaboration (CKD-EPI) equation at the time of screening.\n15. Active malignancy requiring chemotherapy and\u002For radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment.\n16. Hypersensitivity or adverse reactions (e.g, urticaria, breathing difficulty, severe hypotension, or anaphylaxis) to human blood products such as human IgG, albumin, or other blood components.\n17. Known history of immunoglobulin A (IgA) deficiency.\n18. Known history of autoimmune nodo-paranodopathies causing IG treatment resistance, including anti-neurofascin (NF) 186 antibodies and antibodies against paranodal proteins, such as NF155, contactin 1 (CNTN1), and contactin-associated protein 1 (CASPR1).\n19. Abnormal laboratory values at screening:\n\n    1. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\> 2.5x upper limit of normal (ULN)\n    2. Platelet count \\\u003C100,000 cells\u002FµL.\n    3. Absolute neutrophil count (ANC) \\\u003C1000 cells\u002FµL.\n    4. Clinically significant anemia or hemoglobin (Hgb) level of \\\u003C 10.0 g\u002FdL at screening.\n20. Ongoing\u002Factive infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV Type 1\u002F2 infection. Participants with chronic hepatitis B or hepatitis C infection currently on treatment may participate if they have undetectable viral load within 12 months of screening date.\n21. Subjects who have received:\n\n    1. Within 2 months before wash-out phase:\n\n       * PE\n       * change in treatment of methotrexate, azathioprine, or mycophenolate\n    2. Within 3 months before wash-out phase: Efgartigimod alfa (Vyvgart)\n    3. Within 5 months before wash-out phase: cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, or any other immunosuppressive medications\n    4. Within 12 months before wash-out phase: rituximab or alemtuzumab\n22. Participants who have received a hematopoietic stem cell transplant.\n23. Participants on corticosteroids for the treatment of CIDP after being fully washed out. Participants on maintenance doses of corticosteroid may be allowed, if treatment is for conditions unrelated to CIDP (doses usually below 20 mg\u002Fday prednisone or equivalent and where the dosage is unlikely to be tapered during the duration of the trial may be allowed for indications other than CIDP).\n24. Any disorder or condition that in the investigator's judgment may impede the participant's participation in the study, pose increased risk to the participant, or confound the results of the study.\n25. Participation in another clinical study involving an investigational medicinal product (IMP) or investigational device within 30 days prior to screening visit or within 5 half-lives of the IMP under investigation or is scheduled to participate in another clinical study involving an IMP or investigational device during the intended course of this study.\n26. History of acquired or inherited thrombophilic disorders. These will include the specific types of acquired or inherited thrombophilic disorders that could put participants at risk of developing thrombotic events. Examples include, but are not restricted to:\n\n    1. Hereditary thrombophilia, examples include\n\n       * Factor V Leiden mutation.\n       * Prothrombin 20210A mutation.\n       * Protein C deficiency.\n       * Protein S deficiency.\n       * Antithrombin deficiency.\n    2. Acquired thrombophilias, examples include:\n\n       * Antiphospholipid antibody syndrome.\n       * Activated protein C Resistance acquired.\n       * Homocysteinemia.\n27. Previous participation in this clinical study, except for participants who withdrew consent during the washout phase, prior to randomization.\n28. Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.",{"count":96,"type":21},161,[24],"The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.",[27],[27,101,102,103,104,105],"CIDP","Intravenous","Human Immunoglobulin","KIg10","QIVIGY",{"date":80,"type":32},{"date":108,"type":21},"2026-06",{"date":110,"type":21},"2027-12-27",{"name":112,"class":39},"Kedrion S.p.A.",3,{"id":115,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":25,"conditions":118,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":124,"locationsCount":125},"100538385",{"count":20,"type":21},[24],[27],"2026-06-12",{"date":121,"type":32},"2026-06-15",{"date":34,"type":32},{"date":36,"type":21},{"name":38,"class":39},128,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100599987","phase-3-a-study-to-assess-the-efficacy-and-safety-of-empasiprubart-in-adults-with-cidp-100599987","NCT07091630","A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP","A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy","emnergize","Inclusion Criteria:\n\n* Meets criteria for CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP\n* Has residual disability and active disease\n* Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)\n* Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP\n\nExclusion Criteria:\n\n* Meets the criteria for possible CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Sensory CIDP (including sensory-predominant CIDP)\n* Polyneuropathy of other causes\n* Clinical diagnosis of systemic lupus erythematosus (SLE)\n* Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation",{"count":20,"type":21},[24],"The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Femnergize",[27,101,138],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","2026-06-11",{"date":119,"type":32},{"date":142,"type":32},"2025-09-16",{"date":144,"type":21},"2031-01-23",{"name":146,"class":39},"argenx",61,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100586793","phase-3-a-study-to-assess-efficacy-and-safety-of-empasiprubart-versus-ivig-in-adults-with-cidp-100586793","NCT06920004","A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP","A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy","emvigorate","Inclusion Criteria:\n\n* Meets criteria for CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP\n* Has responded to IVIg in the past 5 years\n* Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g\u002Fkg\n* Has residual disability and active disease\n\nExclusion Criteria:\n\n* Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes\n* Meets the criteria for possible or sensory CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Use of other long-acting immunomodulatory treatment",{"count":157,"type":21},218,[24],"The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Femvigorate",[27,101,161],"CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",{"date":119,"type":32},{"date":164,"type":32},"2025-08-22",{"date":166,"type":21},"2030-09",{"name":146,"class":39},75,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100595454","phase-2-imeroprubart-in-adult-participants-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100595454","NCT07032662","Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Inclusion Criteria:\n\n* Have met clinical diagnostic criteria for typical CIDP or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology\u002FPeripheral Nerve Society (EAN\u002FPNS) Guideline on Diagnosis and Treatment of CIDP.\n* Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN\u002FPNS guideline on diagnosis and treatment of CIDP.\n* Are currently on, and have been receiving chronic, stable doses of systemic corticosteroids (i.e., daily or every other day oral or pulse regimen), or immunoglobulin therapy (IVIg or SCIg) ± low dose oral corticosteroids for at least 3 months for the treatment of CIDP at the time of the Screening Visit.\n\nAdditional inclusion criteria are defined in the protocol.\n\nExclusion Criteria:\n\n* Have current or prior history of IgM paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies.\n* Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy per the EAN\u002FPNS guideline on diagnosis and treatment of CIDP.\n* Have polyneuropathy of causes other than CIDP including but not limited to:\n\n  * Multifocal motor neuropathy\n  * Hereditary demyelinating neuropathy\n  * Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS)\n  * Lumbosacral radiculoplexus neuropathy\n  * Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies\n  * Drug- or toxin-induced\n* Have diabetes mellitus (DM) and meets any of the following criteria:\n\n  * Does not have both typical CIDP and strong evidence of demyelination on nerve conduction study.\n  * In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP.\n  * In the opinion of the Investigator, there is evidence of poorly controlled DM at screening.\n* Have a history of myelopathy or evidence of central demyelination. Additional exclusion criteria are defined in the protocol.",{"count":177,"type":21},162,[179],"PHASE2","This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.",[27],[27,183,184,185,101,186],"IMVT-1402","Monoclonal antibody","Human immunoglobulin G1 (IgG1)","Imeroprubart","2026-06-05",{"date":189,"type":32},"2026-06-08",{"date":191,"type":32},"2025-03-18",{"date":193,"type":21},"2030-05",{"name":195,"class":39},"Immunovant Sciences GmbH",135,{"id":198,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":53,"conditions":201,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":206,"leadSponsor":207,"locationsCount":208},"100582074",{"count":51,"type":21},[24],[27],"2026-05-29",{"date":204,"type":32},"2026-06-02",{"date":57,"type":32},{"date":59,"type":21},{"name":61,"class":39},168,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":220,"conditions":221,"keywords":238,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":253},"100629707","effects-of-whole-body-electrical-muscle-stimulation-exercise-on-adults-with-neuromuscular-disease-100629707","NCT07478172","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults withNeuromuscular Disease","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with one or more of the following neuromuscular conditions: Amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscle atrophy, spinal muscular atrophy, postpolio syndrome, inclusion body myositis, pompedisease, fascioscapulohumeral muscular dystrophy, charcot marie tooth disease, chronic inflammatory demyelinating polyneuropathy, hereditary spastic paraplegia, myasthenia gravis, lambert-eaton myasthenic syndrome, postural orthostatic tachycardia syndrome, mitochondrial myopathy, nemaline myopathy, centronuclear myopathy, lumbar radiculopathy, non-specific low back pain.\n* Ability to stand for approximately 15 minutes continuously with or without an assistive device (i.e. the length of time to stand to take a shower, complete meal preparation, wait in line at the bank, etc.)\n* At least some anti-gravity strength in major muscle groups as assessed by manual muscle testing (i.e. 2+\u002F5 strength or better)\n* Medical clearance to participate in an exercise program\n* Ability to provide informed consent\n* Ability to conform to the requirements of the study (i.e. attendance at assessment and intervention visits, maintain current level of non-study physical activity for the duration of the study, no intention to relocate mid-study)\n\nExclusion Criteria:\n\n* Diagnosed with one of the following neuromuscular conditions: Becker's muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myotonic dystrophy type 1 or 2, Freidrich's ataxia, any other NMD with known or suspected cardiac involvement or muscle fiber structural integrity defects.\n* Concurrent participation in another interventional research study\n* Unable to tolerate 15 minutes of continuous standing with or without an assistive device\n* Presence of a pacemaker, metal implants, or other implanted medical devices that could impact participant safety during WB-EMS intervention\n* Presence of cochlear implant, cortical stimulator, deep brain stimulator, ventriculoperitoneal shunt, recent skull defect, seizure in the past 12 months while taking anti-epilepsy medication, or previous serious adverse event with TMS, which could impact participant safety during TMS testing\n* Presence of unstable acute or chronic disease (i.e. renal failure, rheumatologic disease, cardia arrhythmia, neoplasm, uncontrolled hypertension)\n* Known pregnancy at time of screening; verbal screening will occur throughout the study.\n* Presence of a terminal disease (i.e. receiving hospice services)\n* Current or previous use of any drugs known to influence muscle mass or performance within 6 months; these may include but are not limited to anabolic steroids, IGF01, growth hormone, replacement androgen therapy, anti-androgen therapy\n* Presence of an additional neurologic conditions affecting somatosensory or motor function\u002Fcontrol (i.e. Parkinson's disease, Multiple Sclerosis, h\u002Fo stroke, TBI, SCI, ataxia, apraxia, hemiplegia, etc.)\n* Musculoskeletal condition or surgery in the past year that would confound results of exercise interventions (i.e. TKA, THA, RTC repair, spinal fusion)\n* Other medical conditions, signs, or symptoms that would interfere with study conductor interpretation of results as determined by an investigator",{"count":217,"type":21},50,[219],"NA","This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50 adults with conditions like ALS, SMA, and MG will undergo 20-minute supervised WB-EMS sessions (1-2 times weekly for 4-8 weeks) using the Katalyst system. Outcomes include neural excitability (TMS), motor unit behavior (EMG, NCS), functional tests (walk, balance, strength), and patient-reported fatigue, pain, and quality of life. Strict safety monitoring and exclusion criteria are in place. This study will provide preliminary data on WB-EMS as a potential exercise modality for NMD.",[222,223,76,224,225,226,227,228,229,230,231,232,233,234,27,235,236,237],"Neuromuscular Diseases (NMD)","Amyotrophic Lateral Sclerosis","Lambert-eaton Myasthenic Syndrome","Primary Lateral Sclerosis","Spinal Muscular Atrophy","Charcot Marie Tooth Disease (CMT)","Fascioscapulohumeral Muscular Dystrophy","Inclusion Body Myositis","Mitochondrial Myopathy","Nemaline Myopathy","Centronuclear Myopathy","Postpolio Syndrome","Pompe Disease (Late-onset)","Hereditary Spastic Paraplegia","Postural Orthostatic Tachycardia Syndrome (POTS)","Progressive Muscular Atrophy",[239,240,241,242],"Neuromuscular Disease","Electrical Stimulation","Whole Body stimulation","Exercise intervention","2026-03-12",{"date":245,"type":32},"2026-03-17",{"date":247,"type":32},"2026-03-10",{"date":249,"type":21},"2031-01-07",{"name":251,"class":252},"University of Missouri-Columbia","OTHER",1,{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":264,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":253},"100484176","phase-1-ivig-vs-scig-in-cidp-100484176","NCT05584631","IVIG vs SCIG in CIDP","The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration","Inclusion Criteria:\n\n* Patients aged \\>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences \u002F Peripheral Nerve Society CIDP diagnostic criteria).\n* 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg\u002Fkg dose for SCIG.\n\nExclusion Criteria:\n\n* Patients receiving IVIG for indications other than CIDP will be excluded.\n* Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \\\u003C 50 mL\u002Fmin) will be excluded\n* Active malignancies\n* Diabetes\n* Myasthenia gravis\n* Immunodeficiency\n* Autoimmune disease","65 Years",{"count":263,"type":21},20,[73],"Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.",[101,267,27],"Immunoglobulin Deficiency",[269,270,271],"immunoglobulin","pharmacokinetics","obesity","2025-12-10",{"date":274,"type":32},"2025-12-11",{"date":276,"type":32},"2022-09-11",{"date":278,"type":21},"2026-12-01",{"name":280,"class":252},"Rutgers, The State University of New Jersey",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":290,"phases":4,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":253},"100604823","immunoadsorption-for-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100604823","NCT07154524","Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","IFTOC","Inclusion Criteria:\n\n* Diagnosis of CIDP based on the EAN\u002FPNS Guidelines on Diagnosis and Treatment of CIDP13\n* age ≥ 18 years\n* Willing and capable of giving written informed consent\n* Currently receiving IVIg or MP treatment OR starting IVIg or MP treatment at baseline\n\nExclusion Criteria:\n\n* none",{"count":289,"type":21},140,"OBSERVATIONAL","This study is designed as an explorative study aiming at exploring safety and efficacy of immunoadsorption (IA) in patients with Chronic Inflammatory Demyelinating Poly-neuropathy (CIDP) compared to intravenous immunoglobulins (IVIg) and methyl-prednisolone (MP). For this purpose, approximately 140 patients with CIDP will be included within the framework of the German multicenter network \"Kompetenznetz Peripherer Nerv\" (KKPNS).\n\nThe study will be purely observational. IA will be performed as an escalation therapy, i.e., in patients who did not respond to IVIg and\u002For MP treatment. Patients will be included in the study during ongoing IVIg or MP treatment and switched to IA during the 18-month observation period in case of an insufficient response. IA will be performed according to the therapeutic scheme of each participating center. A non-mandatory recommendation for number of sessions, treatment volumes, and frequency will be given (see below). Six-month follow-up visits including collection of standardized clini-cal data will be performed.",[27],[27,294,295,296],"Immunoadsorption","Long-term effects","therapy-refractory","2025-09-04",{"date":299,"type":32},"2025-09-11",{"date":301,"type":32},"2025-08-27",{"date":303,"type":21},"2029-08-27",{"name":305,"class":252},"University of Ulm",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":313,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":290,"phases":4,"briefSummary":315,"conditions":316,"keywords":319,"overallStatus":323,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":253},"100440108","nt-3-levels-and-function-in-individuals-with-cmt-100440108","NCT05011006","NT-3 Levels and Function in Individuals With CMT","Correlation of Circulating NT-3 Levels and Function in Individuals With Peripheral Neuropathy or Charcot-Marie-Tooth Neuropathy","Inclusion Criteria:\n\n* Males or females from 7 years of age or older\n* Diagnosis of acquired peripheral neuropathy (PN) such as due to diabetes, chemo-induced, autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP) established by a report of electrical studies or with a known genetic CMT diagnosis. Definitive diagnosis of PN is established with a report of electrical studies, EMG\u002Fnerve conduction studies.2\n* Perform assessments to the best of their ability with reliable results as deemed by the evaluator.\n* Ability to attend scheduled appointments\n* Ability to provide informed consent (or assent for ages 9-18)\n\nExclusion Criteria:\n\n* Current pregnancy per medical history\n* Has a medical condition or extenuating circumstances that, in the opinion of the investigator, might compromise the subject's wellbeing, safety, or clinical interpretability","7 Years",{"count":217,"type":21},"This study will assess the serum NT-3 levels in individuals with the diagnosis of peripheral neuropathy or any type of Charcot-Marie-Tooth Neuropathy (CMT) and correlate this with function.",[317,318,27],"Charcot-Marie-Tooth Disease","Peripheral Neuropathy",[320,321,322],"NT-3","CMT1A","Neuropathy","NOT_YET_RECRUITING","2025-06-18",{"date":326,"type":32},"2025-06-24",{"date":328,"type":21},"2027-11-13",{"date":330,"type":21},"2030-06",{"name":332,"class":252},"Zarife Sahenk",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":341,"targetDuration":343,"studyType":290,"phases":4,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":323,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":4},"100593450","vitaccess-real-cidp-registry-100593450","NCT07006597","Vitaccess Real CIDP Registry","Vitaccess Real CIDP Registry: A Prospective International Observational Patient Registry in Chronic Inflammatory Demyelinating Polyneuropathy Linking Clinical and Patient-Reported Data","VRCIDP","Inclusion Criteria:\n\n* Adult (age ≥18 years) with a clinically confirmed diagnosis of CIDP by their treating neurologist\n* Resident in the US, UK or Germany\n* Access to a smartphone\u002Ftablet\u002Fcomputer\u002Flaptop\n* Willing and able to provide informed consent in their local language to take part in the study\n\nExclusion Criteria:\n\nNone",{"count":342,"type":21},300,"10 Years","Vitaccess Real CIDP (VRCIDP) is a patient registry designed to capture longitudinal observational data on chronic inflammatory demyelinating polyneuropathy (CIDP), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 300 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from electronic medical records (EMR). Patient reported and eCRF data will be linked via a unique ID and PIN assigned to each participant at enrolment.\n\nPatients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.",[27,101],[347,348,349,350,351,352,353,354],"patient registry","longitudinal observational data","patient-reported outcomes","Nervous System Disease","Autoimmune Disease","Neurodegenerative Disease","Immune System Disease","Nervous System Diseases","2025-06-04",{"date":357,"type":32},"2025-06-05",{"date":359,"type":21},"2025-07-31",{"date":361,"type":21},"2035-07",{"name":363,"class":39},"Vitaccess Ltd",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":290,"phases":4,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":253},"100530197","exploratory-study-on-predicting-cidp-patients-decline-during-iv-immunoglobulin-treatment-adaptation-feasibility-100530197","NCT06183645","Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.","ActiCIDP : Exploratory Study on the Feasibility of Predicting CIDP Patients' Evolution Decline During Intravenous Immunoglobulins Treatment Adaptation.","ActiCIDP","Inclusion Criteria:\n\n* Diagnosed with CIDP or possible CIDP based on 2021 EAN\u002FPNS criteria2.\n* Treated with IVIg (≤1g\u002Fkg\u002F3-8week)\n* Clinically Stable disease for 3 months (according to treating physician opinion).\n* No treatment withdrawal failure within 1 year\n* Age over 18 years\n\nExclusion Criteria:\n\n* Significant cognitive or communication disorders\n* Surgery or serious traumatic injury ≤ 6 months\n* Non ambulant patient\n* Current participation to a therapeutic trial\n* Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy\n* Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment\n* Pregnancy or breastfeeding\n* Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.","99 Years",{"count":374,"type":21},40,"ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis.\n\nThe investigators plan to include a group of approximately 40 patients with CIDP.\n\nThe investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.",[27],[378,379,380],"Actimyo","Accelerometry","Daily living",{"date":382,"type":32},"2025-02-12",{"date":384,"type":32},"2023-08-28",{"date":386,"type":21},"2028-01",{"name":388,"class":252},"Centre Hospitalier Universitaire de Liege",{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":290,"phases":4,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":413},"100414139","hizentra-in-inflammatory-neuropathies---phenix-study-100414139","NCT04672733","Hizentra® in Inflammatory Neuropathies - pHeNIx Study","pHeNIx","Inclusion Criteria:\n\n* Adult patient (aged ≥18 years)\n* Patients suffering from CIDP according to EAN\u002FPNS 2021 criteria\n* Planned switch from IVIg to Hizentra®\n* Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins\n* Patient deemed to be stable, with no change in their treatment for the disease during the 3 months prior to inclusion\n* Patients who have a smartphone, a tablet or a computer\n* Patients who have been informed verbally and in writing of the purposes of the study\n\nExclusion Criteria:\n\n* Concomitant participation in an interventional clinical study",{"count":397,"type":21},100,"The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).",[27],[101,401,402,403],"IgPro20","Hizentra","Subcutaneous Immunoglobulins","2025-01-06",{"date":406,"type":32},"2025-01-07",{"date":408,"type":32},"2022-06-10",{"date":410,"type":21},"2027-12",{"name":412,"class":39},"CSL Behring",27,{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":290,"phases":4,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":323,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":4},"100456115","clinical-and-electrophysiological-patterns-of-chronic-dysimmune-polyneuropathy-100456115","NCT05219383","Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy","Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy Among Patients Attending Neuropsychiatry Department - Assiut University","Inclusion Criteria:\n\n* Age \\> 18 years, both sexes, history of sensory and\u002For motor complaint with progressive course over more 2 months\n\nExclusion Criteria:\n\n* \\*Patients with systemic diseases (DM, chronic kidney or liver disease, thyroid disease, vitamin B12 deficiency)\n\n  * Family history of peripheral neuropathy or neurological symptoms suggestive for heredo-familial neurological disorders\n  * Patients with infective cause as (HBV, HCV, HIV, leprosy)\n  * Toxic and drug induced polyneuropathy (chemotherapeutics, antimicrobial ..","80 Years",{"count":423,"type":21},36,"Chronic dysimmune neuropathies (CDN) are a heterogenous group of acquired inflammatory demyelinating neuropathies including chronic inflammatory demyelinating polyneuropathies (CIDP), Lewis-Sumner Syndrome (LSS), multifocal motor neuropathy (MMN) and other rare entities.\n\nDespite their relatively low prevalence, CDN lead to substantial costs for patients and society. CDN are usually misdiagnosed due to progressive nature of the disease with little known data regarding disease activity and treatment response",[27],"2022-01-20",{"date":428,"type":32},"2022-02-02",{"date":430,"type":21},"2023-01",{"date":432,"type":21},"2026-12",{"name":434,"class":252},"Assiut University"]